Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837993 | 0.86 | AVPR1A (0.59) | P2RX7AVPR1ANPY5R | |
| SCHEMBL3836464 | 0.85 | HRH3 (0.49) | P2RX7AVPR1ANPY5RCNR1 | |
| SCHEMBL4987131 | 0.83 | AVPR1A (0.56) | P2RX7AVPR1ANPY5R | |
| SCHEMBL3844843 | 0.82 | HSD11B1 (0.49) | AVPR1ANPY5R | |
| SCHEMBL3841668 | 0.80 | HRH3 (0.49) | P2RX7AVPR1ANPY5RCNR1 | |
| SCHEMBL4355431 | 0.78 | AVPR1A (0.80) | AVPR1ANPY5RCNR1 | |
| SCHEMBL5138467 | 0.78 | AVPR1A (0.80) | AVPR1ANPY5RCNR1 | |
| SCHEMBL3842034 | 0.77 | AVPR1A (0.46) | P2RX7AVPR1ANPY5RCNR1 | |
| SCHEMBL4359175 | 0.76 | AVPR1A (0.48) | P2RX7AVPR1ANPY5RCNR1 | |
| SCHEMBL4364621 | 0.76 | AVPR1A (0.49) | AVPR1ANPY5RCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | claimed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | claimed |
| EP-2535329-A2 | Spiro-piperidine derivatives | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| EP-2535329-A2 | Spiro-piperidine derivatives | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2097376-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008077810-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008077810-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | P2RX7 74/4885AVPR1A 1/4885NPC1 2303/4885 |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | P2RX7 74/4885AVPR1A 1/4885NPC1 2303/4885 |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | P2RX7 74/4885AVPR1A 1/4885NPC1 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.